🇺🇸 FDA
Patent

US 9951118

Engineering antiviral T cell immunity through stem cells and chimeric antigen receptors

granted A61KA61K2239/31A61K2239/38

Quick answer

US patent 9951118 (Engineering antiviral T cell immunity through stem cells and chimeric antigen receptors) held by The Regents of the University of California expires Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Apr 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
26
CPC classes
A61K, A61K2239/31, A61K2239/38, A61K35/28, A61K40/11